Author

M. Tsoumakidou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

D. Kerdidani· 2 shared E. Aerakis· 2 shared A. Chatzigeorgiou· 1 shared A. Galaras· 1 shared A. Koutsopoulos· 1 shared A. Prados· 1 shared A. Vlahou· 1 shared B. Malissen· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Kerdidani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Interferon-induced lysosomal membrane permeabilization and death cause cDC1-deserts in tumors.

E. Aerakis, A. Chatzigeorgiou, M.-M. Alvanou, M. Matthaiakaki-Panagiotaki, I. Angelidis, D. Koumadorakis, A. Galaras, P. Hatzis, D. Kerdidani, M. Makridakis, A. Vlahou, B. Malissen, S. Henri, M. Merad, M. Tsoumakidou

This study identifies interferon-induced lysosomal membrane permeabilization and death as mechanisms causing cDC1 scarcity in tumors, suggesting therapeutic strategies to enhance anti-tumor immunity.

bioRxiv · Mar 14, 2022 · PreprintImmunology

Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.

D. Kerdidani, E. Aerakis, K.-M. Verrou, P. Stamoulis, K. Goudevenou, A. Prados, C. Tzaferis, I. Vamvakaris, E. Kaniaris, K. Vachlas, E. Sepsas, K. Potaris, A. Koutsopoulos, M. Tsoumakidou

This study shows that cancer-associated fibroblasts present antigens in situ to activate CD4 T cells, enhancing tumor immunity and suggesting new therapeutic strategies.

bioRxiv · Mar 24, 2020Immunology